Interview with the CEO, President, Executive Vice Chairman, Secretary, General Counsel and Litigation Counsel and the Chairman: Hemispherx Biopharma, Inc. (NYSEMKT:HEB)

Healthcare >> CEO Interviews >> August 12, 2016

Thomas K. Equels, M.S., J.D., was named Chief Executive Officer in February 2016, served as President since August 2015, has been a director since 2008 and presently serves as our Executive Vice Chairman, Secretary, and General Counsel and Litigation Counsel of Hemispherx Biopharma, Inc. Mr. Equels previously served as Chief Financial Officer from December 2013 to February 2016. Also, for over a quarter century, Mr. Equels has represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. He has extensive experience in international business matters. On numerous occasions, Mr. Equels has served as a court-appointed receiver/chief executive for distressed businesses. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Master of Science degree from Troy. He is a member of the Florida Bar Association and the American Bar Association. Profile

William M. Mitchell, M.D., Ph.D., was appointed Chairman of the board of Hemispherx Biopharma, Inc., in February 2016 after serving as a director since July 1998. Dr. Mitchell is a professor of pathology, microbiology and immunology at Vanderbilt University School of Medicine and is a board-certified physician. Dr. Mitchell earned an M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as House Officer in Internal Medicine — Osler Service — followed by a fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts that relate to the pathogenesis of obligate intracellular pathogens, innate and adaptive immune responses, and liquid biopsy cancer — chromosomal instability — diagnostics. He is the inventor or co-inventor of 14 issued U.S. patents as well as derivative foreign patents. Dr. Mitchell has worked with many professional societies that have included the American Society of Investigative Pathology, or ASIP; the International Society for Antiviral Research, or ISAR; the American Society of Biochemistry and Molecular Biology, or ASBMB; the American Society of Microbiology, or ASM; the American Chemical Society, or ACS; and the American Society of Clinical Oncology, or ASCO. Dr. Mitchell is a member of the American Medical Association, or AMA. He has served on numerous review committees for the National Institutes of Health, or NIH; the Centers for Disease Control, or CDC; the European Union, or EU; and the College of American Pathology, or CAP. He is an independent director of Chronix Biomedical, a genetics-based cancer diagnostic company. Profile

TWST: Can you offer a brief overview of the company, and your core technology and how that technology would differ generally from the standard of care today?

Mr. Equels:

Join for free to read a longer excerpt or purchase this article
Already a member? Login here

Interview with the CEO, President, Executive Vice Chairman, Secretary, General Counsel and Litigation Counsel and the Chairman: Hemispherx Biopharma, Inc. (NYSEMKT:HEB)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the CEO, President, Executive Vice Chairman, Secretary, General Counsel and Litigation Counsel and the Chairman: Hemispherx Biopharma, Inc. (NYSEMKT:HEB)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS